These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11233228)

  • 1. [Omnic (tamsulosin) in the treatment of benign prostatic hyperplasia].
    Lopatkin NA; Pytel' IuA; Trapeznikova MF; Loran OB; Mazo EB; Stepanov VN; Gres' AA; Savchenko NE; Vozianov AF; Babich VM
    Urologiia; 2001; (1):3-8. PubMed ID: 11233228
    [No Abstract]   [Full Text] [Related]  

  • 2. Benign prostatic hyperplasia: maximizing treatment with alpha blockers.
    Lowenthal DT; Flannery M; Mader SL; Nelson RP
    Geriatrics; 1998 Oct; 53 Suppl 2():S4-28. PubMed ID: 9789482
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamsulosin MR and OCAS (modified release and oral controlled absorption system): current therapeutic uses.
    Nargund VH; Grey AD
    Expert Opin Pharmacother; 2008 Apr; 9(5):813-24. PubMed ID: 18345957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical trends in administration of the alpha1A-adrenoblocker Omnik (tamsulosin) in urological practice].
    Mazo EB; Sukhanov SV
    Urologiia; 2003; (4):49-52. PubMed ID: 12942729
    [No Abstract]   [Full Text] [Related]  

  • 8. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness of various alfuzosin schedules in patients with benign prostatic hyperplasia (BPH)].
    Loran OB; Rasner PI; Kosko D; Pushkar' DIu
    Urologiia; 2001; (1):8-10. PubMed ID: 11233234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RBx 6198: a novel alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia.
    Nanda K; Naruganahalli KS; Gupta S; Malhotra S; Tiwari A; Hegde LG; Jain S; Sinha N; Gupta JB; Chugh A; Anand N; Ray A
    Eur J Pharmacol; 2009 Apr; 607(1-3):213-9. PubMed ID: 19239913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expediency of switching from combined therapy with prostamol Uno and alpha-1-adrenoblockers to monotherapy with prostamol Uno in patients with prostatic adenoma].
    Razumov SV; Egorov AA
    Urologiia; 2007; (3):47-50. PubMed ID: 17724829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
    Kojima Y; Sasaki S; Kubota Y; Hayase M; Hayashi Y; Shinoura H; Tsujimoto G; Kohri K
    J Urol; 2008 Mar; 179(3):1040-6. PubMed ID: 18206918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting.
    Flannery MT; Ramsdell J; Ranhosky A; Davidai G; Ruoff G
    Curr Med Res Opin; 2006 Apr; 22(4):721-30. PubMed ID: 16684433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
    Lowe FC
    Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tamsulosin in the sustained-release capsule -- continuously effective and economical].
    MMW Fortschr Med; 2006 Apr; 148(17):56-7. PubMed ID: 16711490
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
    Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
    BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
    Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
    Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report.
    Palacio A; Hernández C; Marqués A; Prats J; Espinosa FJ
    Arch Esp Urol; 2004 May; 57(4):451-60. PubMed ID: 15270291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of combined treatment of prostatic gland after biopsy of the prostate for an elevated PSA level].
    Okhrits VE; bogdanov AB; Veliev EI
    Urologiia; 2009; (6):39-43. PubMed ID: 20169722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.